This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

FLEXISEQ® Wins BVDA Innovation Of 2013 Award: Innovative New Treatment For The Symptoms Of Osteoarthritis

Professor Herbert Kellner, Munich, one of the panellists at the BVDA awards said, "More than 50% of people over 65 have already developed OA and its prevalence is as high as 90% in people over 75. Thus OA is of enormous social and economic significance."

Patients with OA suffer from chronic pain and joint stiffness. "NSAID's and COX II's are frequently used without critical evaluation", said Professor Martin Wehling, of The University of Heidelberg, a specialist in elderly patients with cardiovascular conditions. "However, this class of drugs is associated with a high risk." He estimated that every year more than 3,000 patients die from bleeding complications in Germany alone. Wehling said that he was acutely aware that many OA patients also have other health issues such as cardiovascular conditions and hence NSAIDs/COX II are contra indicated or must only be used with caution in patients. In addition, chronic NSAID use is associated with approximately 20 other severe side effects. FLEXISEQ now provides a more appropriate and safer solution for these patients. This enables sufferers to avoid drug to drug interactions with other medicines which they may need to take for other common diseases. FLEXISEQ does not contain any pharmacological ingredients but provides a physical rather than chemical based treatment for this painful and debilitating disease. This physical approach avoids many of the significant side effects of conventional chemical based treatments alluded to by Professor Wehling.

Dr Matthias Rother, Munich, who was instrumental to the development of SequessomeTechnology, explained that "FLEXISEQ was evaluated in a comprehensive clinical trial programme: 1,675 patients were treated with FLEXISEQ in six studies. Even for a treatment period, within one of the trials of up to 52 weeks, FLEXISEQ was well tolerated."

Michael Earl, Chief Operating Officer of Pro Bono Bio, who own FLEXISEQ, said "Leading Rheumatologists are concerned about the limited treatments available for OA sufferers and also about the side effects of some existing therapies.  FLEXISEQ is an important part of the answer to these concerns.  Its launch in its home market of Germany in 2012 drew a lot of attention from physicians and pharmacists. We are delighted to win the BVDA Innovation Award 2013, and encourage German patients to visit their local pharmacist to find out more about this exciting development for the millions of sufferers of Osteoarthritis in Europe. We are also delighted we have already started to export FLEXISEQ to Asia where the product has received a very warm welcome."

Separately from the BVDA award, German patients are already benefiting from the treatment. One patient who wishes to remain anonymous reported, "I started using FLEXISEQ on the 3rd January 2013. Before then, I was hardly able to walk properly, sometimes I used walking aids but did not get further than 60 m and I was in a lot of pain. I heard about FLEXISEQ on 'Feierabend.de' and I AM VERY HAPPY! Now I can already walk 1.5 km - without pain!! I have an appointment for a scan of my knee in a clinic on the 3rd of April, but I am unsure whether to attend the appointment."

About Pro Bono Bio™                    

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,678.70 +6.10 0.03%
S&P 500 2,057.09 +5.27 0.26%
NASDAQ 4,771.7630 +13.8840 0.29%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs